NCT01217788 (PH94B-SAD) is a Phase 2 clinical trial of PH94B intranasal spray in Social Phobia, sponsored by Pherin Pharmaceuticals, Inc..

Who is sponsoring NCT01217788?

NCT01217788 is sponsored by Pherin Pharmaceuticals, Inc..

What drugs are being tested in NCT01217788?

Interventions in NCT01217788: PH94B intranasal spray.

What condition does NCT01217788 study?

NCT01217788 studies Social Phobia, Social Anxiety Disorder.

Is NCT01217788 still recruiting?

NCT01217788 is currently completed. Last updated 9 May 2011.

Last reviewed 2011-05-09 · How we verify

NCT01217788: PH94B-SAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double Blind Placebo Controlled Study of PH94B for Management of the Symptoms of Generalized Social Phobia

Completed Phase 2 Last updated 9 May 2011

What this trial tests

Phase 2 trial testing PH94B intranasal spray in Social Phobia in 90 participants. Completed in 1 March 2011.

Timeline

1 February 2008

Primary endpoint
1 February 2011

1 March 2011

Quick facts

Lead sponsor	Pherin Pharmaceuticals, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	90
Start date	1 February 2008
Primary completion	1 February 2011
Estimated completion	1 March 2011
Sites	1 location across United States

Drugs / interventions tested

PH94B intranasal spray — full drug profile →

Conditions studied

Social Phobia — all drugs for Social Phobia →
Social Anxiety Disorder — all drugs for Social Anxiety Disorder →

Sponsor

Pherin Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Social Phobia or Social Anxiety Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Subjective Unit of Discomfort Scale
Time frame: Once before and again 10 minutes after intranasal dosing with PH94B spray, during exposure to a public speaking challenge

Sponsor's own description

The purpose of this study is to determine the efficacy of PH94B, a new class of therapeutic compound, administered intranasally for the management of acute anxiety in patients diagnosed with generalized social phobia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.
Chavda VP, Vora LK, Pandya AK, Patravale VB. · · 2021 · cited 142× · PMID 34332100 · DOI 10.1016/j.drudis.2021.07.021
Novel and Evolving Therapies for COVID-19 Related Pulmonary Complications.
Mehta PP, Dhapte-Pawar VS. · · 2021 · cited 9× · PMID 33640363 · DOI 10.1016/j.amjms.2021.02.019

Verify or expand the search:

Other recruiting trials for Social Phobia

Currently open trials in the same condition.

NCT06564402 — Augmentation of Exposure Using Positive Mental Rehearsal in Individuals With Increased Social Anxiety · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01217788 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pherin Pharmaceuticals, Inc.
Last refreshed: 9 May 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01217788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing